Business
Oncolytics Biotech (R) Announces a Publication Highlighting Synergistic Effect of Pelareorep with a Proteasome Inhibitor in Preclinical Models of Multiple Myeloma
- Combination Synergistic Even in Cells That Have Developed Resistance to Bortezomib - ...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"Oncolytics Biotech (R) Announces a Publication Highlighting Synergistic Effect of Pelareorep with a Proteasome Inhibitor in Preclinical Models of Multiple Myeloma- Combination Synergistic Even in Cells That Have Developed Resistance to Bortezomib- Article Published in the March 12 Edition of the Journal Blood AdvancesCALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / March 28, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an article highlighting the synergistic effect of oncolytic immunotherapy in combination with a proteasome inhibitor in the treatment of multiple myeloma. The article, entitled, \"Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model,\" co-authored by Oncolytics' President and Chief Executive Officer, Dr. Matt Coffey was published in the March 12 edition of Blood Advances.The article demonstrates that the combination of reovirus and bortezomib can overcome drug resistance, a major hurdle in the treatment of multiple myeloma. Further, the combination modifies the tumor microenvironment to overcome the immune suppressive environment caused by multiple myeloma cells in the bone marrow. This combination promotes a pro-inflammatory signal within the tumor microenvironment, upregulates the PD-L1/PD-1 axis and enhances immune cell infiltration. Collectively, this suggests the possibility of synergies and increased efficacy with the addition of checkpoint blockade to the combination.\"We'd like to thank our collaborators for this influential work which provides further evidence that the combination of pelareorep with a proteasome inhibitor can synergistically overcome drug resistance and drive enhanced tumor killing and superior overall survival in animal models,\" said Dr. Rita Laufle, Chief Medical Officer of Oncolytics. \"Importantly, the combination engages the immune system in a manner that converts tumor indications that have not been responsive to checkpoint blockade to those that are responsive, by both reversing the immune suppressive aspects of the tumor microenvironment while increasing immune cell trafficking to the tumor and generating new anti-tumor memory T cells. These findings are consistent with our clinical ...